DuoCort Pharma and Recipharm start innovative collaboration
- Details
- Published on Wednesday, 27 October 2010 00:00
Helsingborg/Stockholm – DuoCort Pharma announces it has concluded an agreement with Recipharm under which Recipharm is set to scale-up the manufacturing of DuoCort’s tablets to commercial scale as DuoCort Pharma prepares for market entry with its orphan drug for the treatment of Addison’s disease.
The scale-up agreement represents an innovative risk sharing
collaboration in which Recipharm, one of Europe’s leading pharmaceutical
Contract Development and Manufacturing Organisations, will co-invest in
the scale-up along with DuoCort Pharma.
The Swedish speciality pharma company, DuoCort Pharma, took a step
closer to the market earlier this year when it filed for marketing
authorisation in the EU for its new treatment for the rare and life
threatening disease adrenal insufficiency, often referred to as
Addison’s disease.
Although cortisol replacement therapy for adrenal insufficiency has been
around for a long time, several studies have recorded premature death,
impaired quality of life, increased risk of cardiovascular diseases and
decreased bone mineral density in these patients. Existing replacement
therapies, unable to mimic cortisol’s normal diurnal release profiles,
are viewed as the likely cause of these outcomes.
The new treatment from DuoCort Pharma has a physiological release
profile which mimics the body’s natural release of cortisol, thereby
improving treatment outcomes.
“We are very pleased to be working with an organization of Recipharm’s
calibre to scale-up our tablet manufacturing process. It is a real
endorsement of the quality and commercial potential of our drug
development that Recipharm has chosen to co-invest in this with us,”
commented Maria Forss, CEO of DuoCort Pharma.
“DuoCort Pharma is an industry innovator responsible for developing a
new product for patients in great need of improved medical treatment.
The agreement with DuoCort Pharma fits perfectly with our business model
through which the Recipharm Venture Fund invests in projects where we
can make important contributions through our development and
manufacturing capabilities, both in a short and long term perspective,”
said Carl-Johan Spak, Executive Vice President of Recipharm.
About Recipharm
Recipharm AB is a leading contract development and manufacturing
organisation based in Sweden with 2,000 employees. The company operates
12 development and manufacturing facilities in Sweden, France, the UK,
Spain and Germany and is headquartered near Stockholm. Recipharm
supplies the global pharmaceuticals market with hundreds of different
products in most dosage forms, including solid dose, granulates,
powders, sterile liquids and lyophilisates, semisolids, beta-lactams,
hormones, and inhalers. www.recipharm.com
Contact information
Maria Forss , CEO, DuoCort Pharma, tel +46 70-967 00 07
Carl-Johan Spak, Recipharm, tel +46 70 88 40 154
For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on:
E-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
or
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0)207 861 3019/3043
Download the complete press release here as PDF: 
Download the complete press release in Wordformat here: 